600276 Jiangsu Hengrui Pharmaceuticals
- 46.48
- -0.42-0.90%
Jiangsu Hengrui Pharmaceuticals News
Hengrui Pharma's Unit Gets Regulatory Nod to Trial HRS-5965 Capsules
China's National Medical Products Administration approved Jiangsu Hengrui Pharmaceuticals' (SHA:600276) unit, Chengdu Shengdi Pharmaceutical's application to conduct clinical trials on HRS-5965 capsul
Illustration丨Capital from North China bucked the trend and added positions to Huichuan Technology, Hengrui Pharmaceutical, and Mindray Healthcare
The net sale of A-shares today was 4,044 billion yuan, the second consecutive day of net sales. Among them, Ping An Bank, Guodian Nanrui, and Zhongji Xuchuang received net sales of 255 million yuan, 242 million yuan, and 204 million yuan respectively; Huichuan Technology, Hengrui Pharmaceutical, and Mindray Healthcare bucked the trend and received net purchases of 395 million yuan, 299 million yuan, and 221 million yuan respectively. According to statistics, the capital from North China has been increasing Kweichow Moutai for 3 consecutive days, for a total of 4.265 billion yuan.
Hengrui Pharmaceutical (600276.SH): HRS5580 for injection was approved for clinical trials to prevent nausea and vomiting after surgery
Hengrui Pharmaceutical (600276.SH) announced that recently, the company's subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received the national drug...
Hengrui Pharmaceutical (600276.SH): HRS-5965 capsules obtained drug clinical trial approval notice
Gelonghui May 8 丨 Hengrui Pharmaceutical (600276.SH) announced that its subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd. has received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for HRS-5965 capsules and will conduct clinical trials in the near future. HRS-5965 capsules can inhibit complement system-mediated hemolysis by inhibiting excessive activation of the complement system. Preclinical studies showed that it had a significant inhibitory effect in complement-mediated hemolysis models and was safe.
Hengrui Pharmaceutical (600276.SH): cumulative repurchase of 0.22% of shares
Gelonghui, May 6, 丨 Hengrui Pharmaceutical (600276.SH) announced that as of April 30, 2024, the company had repurchased a total of 14,351,878 shares through centralized bidding transactions, accounting for 0.22% of the company's total share capital. The highest transaction price was 47.01 yuan/share, the lowest price was 41.09 yuan/share, and the total amount paid was 634,665,849.66 yuan (excluding transaction fees).
Hengrui Pharmaceutical (600276.SH) launches phase III study on long-acting insulin+GLP-1 analogue compound formulation
On April 28, the drug clinical trial registration and information disclosure platform showed that Hengrui Pharmaceutical (600276.SH) initiated a phase III clinical trial (CTR20241529) of HR17031 injections with randomized, open, parallel control, and treatment compliance.
Hengrui Pharma Gets Nod to Trial Insulin Aspart Injection; Shares Up 3%
Jiangsu Hengrui Pharmaceuticals (SHA:600276) will conduct clinical trials on insulin aspart injection after receiving approval from China's National Medical Products Administration, according to the c
Why Jiangsu Hengrui Medicine's (SHSE:600276) Earnings Are Better Than They Seem
Despite posting healthy earnings, Jiangsu Hengrui Medicine Co., Ltd.'s (SHSE:600276 ) stock has been quite weak. We have done some analysis, and found some encouraging factors that we believe the sha
Haitong International: Free circuit with long slopes and heavy snow, domestic market space is expected to open up
The Zhitong Finance App learned that Haitong International released a research report saying that compared with innovative domestic drugs to replace relatively mature oncology drugs, self-exempt drugs also have the advantage of a large market size (suitable for the domestic pricing environment for new drugs). The differences are that patients are widely distributed (channel coverage is required), are more chronic diseases, and there is competition for traditional drugs (requiring fast efficacy and high accessibility). Combined with the current market financing environment, although the self-defense target layout is still crowded, companies with good cash flow will be more likely to obtain excess profits. It is recommended to pay attention to Hengrui Pharmaceutical (600276.SH), Kangzhe Pharmaceutical (00867), Sansheng Guojian (688)
Hengrui Pharmaceutical's 2023 performance rebounded steadily, and the sales expense ratio declined year-on-year
On the evening of April 17, Hengrui Pharmaceutical released its 2023 annual report. In 2023, Hengrui Pharmaceutical achieved operating income of 22.82 billion yuan, up 7.26% year on year, net profit attributable to shareholders of listed companies of 4.302 billion yuan, up 10.14% year on year, deducted non-net profit attributable to shareholders of listed companies of 4.141 billion yuan, up 21.46% year on year, net operating cash flow of 7.644 billion yuan, a sharp increase of 504.12% year on year. According to the report's analysis, as Hengrui Pharmaceutical's innovative achievements continue to be approved, the clinical value of innovative drugs is highlighted, driving revenue growth. 2023
Hengrui Pharmaceutical (600276.SH): Injectable carelizumab obtains drug clinical trial approval notice
Gelonghui, April 22丨Hengrui Pharmaceutical (600276.SH) announced that its subsidiary Suzhou Shengdia Biomedical Co., Ltd. has received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for injectable carelizumab and will conduct clinical trials in the near future. Injectable carelizumab is a humanized anti-PD-1 monoclonal antibody that binds to human PD-1 receptors and blocks the PD-1/PD-L1 pathway to restore the body's anti-tumor immunity, thus forming the basis for cancer immunotherapy.
Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) shareholders are probably feeling a little disappointed, since its shares fell 5.5% to CN¥41.68 in the week after its latest quarterly results. T
Hengrui Pharmaceutical (600276.SH): HRS2398 extended-release tablet clinical trial approved
Hengrui Pharmaceutical (600276.SH) issued an announcement. The company's subsidiary Shanghai Hengrui Pharmaceutical Co., Ltd. received national pharmaceuticals...
Hengrui Pharmaceutical (600276.SH): Clinical trials of darsilil hydroxyethanesulfonate tablets and HRS8807 tablets approved
Hengrui Pharmaceutical (600276.SH) issued an announcement. The company and its subsidiary Shanghai Hengrui Pharmaceutical Co., Ltd. received the national drug...
Hengrui Pharma's Units Get Nod to Trial Four Cancer Drugs
Jiangsu Hengrui Pharmaceuticals' (SHA:600276) units will carry out clinical trials on four cancer drugs after receiving the approval of China's National Medical Products Administration, according to t
China Approves Clinical Trials for Hengrui Pharmaceuticals' Lupus, Asthma Drugs
China's National Medical Products Administration approved clinical trials for Jiangsu Hengrui Pharmaceuticals' (SHA:600276) injectables for lupus and MRI imaging, and an asthma inhalant, according to
A Look At The Fair Value Of Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276)
Key Insights The projected fair value for Jiangsu Hengrui Medicine is CN¥40.32 based on 2 Stage Free Cash Flow to Equity Current share price of CN¥45.54 suggests Jiangsu Hengrui Medicine is potentia
Hengrui Pharma's Units Get Approval to Trial Two Gastric Cancer Drugs
Jiangsu Hengrui Pharmaceuticals' (SHA:600276) units obtained approval from China's National Medical Products Administration to trial two gastric cancer drugs, according to the company's filing on the
Hengrui Pharmaceutical (600276.SH): SHR-1139 injection approved for clinical trials
Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, Guangdong Hengrui Pharmaceutical Co., Ltd., a subsidiary of the company, received a national...
Hengrui Pharmaceutical (600276.SH): The subsidiary obtained a notice of approval for clinical trials of the drug
Gelonghui, April 8 | Hengrui Pharmaceutical (600276.SH) announced that its subsidiaries Shanghai Shengdi Pharmaceutical Co., Ltd. and Suzhou Shengdia Biomedical Co., Ltd. have received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for adbelimab injections and SHR-A1811 for injections, and will conduct clinical trials in the near future.
Analysis
Price Target
No Data
